Meta-analysis of the effects of anti-epidermal growth factor receptor on recurrent/metastatic head and neck squamous cell carcinoma (Q61455699)

From Wikidata

Jump to navigation Jump to search

No description defined

edit

Language	Label	Description	Also known as
English	Meta-analysis of the effects of anti-epidermal growth factor receptor on recurrent/metastatic head and neck squamous cell carcinoma	No description defined

Statements

instance of

scholarly article

0 references

meta-analysis

0 references

title

Meta-analysis of the effects of anti-epidermal growth factor receptor on recurrent/metastatic head and neck squamous cell carcinoma (English)

0 references

main subject

head and neck squamous cell carcinoma

1 reference

based on heuristic

inferred from title

author name string

Yong Xin

series ordinal

1

0 references

Qiuyue Yan

series ordinal

2

0 references

ChunSheng Yang

series ordinal

3

0 references

Fan Jiang

series ordinal

4

0 references

Wenwen Guo

series ordinal

5

0 references

Qian Huang

series ordinal

6

0 references

Guan Jiang

series ordinal

7

0 references

Longzhen Zhang

series ordinal

8

0 references

language of work or name

English

0 references

publication date

December 2018

0 references

published in

Medicine

0 references

volume

97

0 references

issue

51

0 references

page(s)

e13717

0 references

cites work

Biological significance of c-erbB family oncogenes in head and neck cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30572506

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The chemoradiation paradigm in head and neck cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30572506

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30572506

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Platinum-based chemotherapy plus cetuximab in head and neck cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30572506

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30572506

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30572506

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacotherapy for squamous-cell carcinoma of the head and neck

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30572506

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular-targeted therapy of head and neck squamous cell carcinoma: beyond cetuximab-based therapy

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30572506

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30572506

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30572506

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-epidermal growth factor receptor therapy for advanced head and neck squamous cell carcinoma: a meta-analysis.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30572506

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30572506

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30572506

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of tumor necrosis factor-alpha promoter variants with risk of HPV-associated oral squamous cell carcinoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30572506

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer statistics, 2014

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30572506

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30572506

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30572506

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30572506

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30572506

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30572506

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30572506

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30572506

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Anti-EGFR monoclonal antibodies in locally advanced head and neck squamous cell carcinoma: a Meta-analysis].

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30572506

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevalence and Outcomes of Head and Neck versus Non-Head and Neck Second Primary Malignancies in Head and Neck Squamous Cell Carcinoma: An Analysis of the Surveillance, Epidemiology, and End Results Database

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30572506

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30572506

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term response in patient with recurrent oropharyngeal carcinoma treated with cetuximab, docetaxel and cisplatin (TPEx) as first-line treatment followed by cetuximab maintenance.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30572506

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tyrosine kinase domain mutations of EGFR gene in head and neck squamous cell carcinoma.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30572506

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Misregulation of DNA damage repair pathways in HPV-positive head and neck squamous cell carcinoma contributes to cellular radiosensitivity

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30572506

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30572506

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypoxia Mediates Differential Response to Anti-EGFR Therapy in HNSCC Cells

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30572506

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Zinc oxide nanoparticles antagonize the effect of Cetuximab on head and neck squamous cell carcinoma in vitro.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30572506

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Locoregionally recurrent head and neck squamous cell carcinoma: incidence, survival, prognostic factors, and treatment outcomes

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30572506

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Repurposing Albendazole: new potential as a chemotherapeutic agent with preferential activity against HPV-negative head and neck squamous cell cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30572506

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30572506

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1097/MD.0000000000013717

0 references

PMC publication ID

6320165

0 references

PubMed publication ID

30572506

0 references

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q61455699&oldid=1502806430"